Cleo Diagnostics

March 2024 Quarterly Activities Report

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to provide the market with an update on activities in the March 2024 quarter as it develops its simple and accurate blood test for the early detection of ovarian cancer.


Highlights

  • Design transfer activities completed, with reliable and reproducible data supporting progression to prototype manufacture
  • Publication of second peer-reviewed dataset confirms substantial performance advantage over current standard of care testing using CA125
  • CLEO’s strategic U.S. market access and reimbursement program underway with appointment of New York-based industry partner HcFocus
  • U.S. clinical trial established, with U.S.-based Lindus Health managing site logistics and patient recruitment
  • Physician engagement commenced in Australia
  • A$9.973M cash at bank at 31 March 2024.

2nd PEER REVIEWED PUBLICATION

The article, entitled ‘Reclassification of patients with ambiguous CA125 for optimised pre-surgical triage’ was published in the peer reviewed medical journal, Diagnostics.

A copy of the publication is available here: https://www.mdpi.com/2075-4418/14/7/671 The article concluded:

a) CLEO’s test correctly identified most cancer cases missed by CA125, including a majority of patients with early stage cancers;

b) The test provided superior identification of benign disease to eliminate the majority of "false positive" results obtained using CA125; and

c) The test efficiently discriminated malignant from benign samples.

Background

Further data for CLEO’s ovarian cancer triage test has been published in the peer-reviewed international journal ‘Diagnostics’.

Whilst these clinical studies are complex documents to interpret for the lay-reader, they form an integral part of Cleo’s commercialisation strategy. They are crucial for providing documentary evidence of Cleo’s test performance and will be used:

  • To support Cleo’s case to be included in national and international medical guidelines;
  • To support Cleo’s applications for private insurance coverage in the USA; and
  • To inform clinicians of Cleo’s test performance to drive uptake.

The latest study assessed the use of CLEO’s triage test to rescue those cases where CA125 provided an incorrect indication. Accurately identifying cancer patients early is critical to provide immediate referral to a gynaecological oncology specialist for surgery; whilst allowing better management of patients with non-malignant disease.

The study compared the potential clinical benefit to patients if CLEO’s Test was used for initial diagnostic work-up instead of CA125, the current gold standard ovarian cancer biomarker.


Click here for the full ASX Release

This article includes content from CLEO Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

COV:AU
The Conversation (0)
CLEO Further Expands Ovarian Cancer Trial with Siles Health

CLEO Further Expands Ovarian Cancer Trial with Siles Health

Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles Health

Download the PDF here.

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Download the PDF here.

illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×